Loading
A phase 1 trial of DT-9081 run by Domain Therapeutics SA, terminated.
DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours is a phase 1 interventional study registered as NCT05582850 by Domain Therapeutics SA, with 29 participants enrolled, started 2022-11-24. Conditions recorded: Solid Tumor, Adult. Interventions recorded: DT-9081 - dose escalation and DT-9081 - expansion.
Shares Kainova Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Kainova Therapeutics and the tag pipeline.
Shares Kainova Therapeutics and the tag pipeline.
Shares Kainova Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/